Brian H. Kushner

Memorial Sloan Kettering Cancer Center — United States

Medicine · Health Sciences

54h-index9.6kcitations276works1.72yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Neuroblastoma Research and Treatments(224), Cancer, Hypoxia, and Metabolism(67), Cancer therapeutics and mechanisms(62), Lung Cancer Research Studies(47), Glioma Diagnosis and Treatment(41)

Publications276 total

Naxitamab plus stepped-up dosing of granulocyte–macrophage colony-stimulating factor for primary refractory high-risk neuroblastoma: results of a phase I/II trial
Journal of Hematology & Oncology·2025Open Access
Local Control With Reduced-Dose Radiation Therapy for High-Risk Neuroblastoma: Results From a Prospective Clinical Trial
International Journal of Radiation Oncology*Biology*Physics·2025
Rapid <scp>COJEC</scp> without myeloablative therapy for high‐risk neuroblastoma
International Journal of Cancer·2025
Clinical Significance of <i>TERT</i> Promoter Mutations in Neuroblastoma
JCO Precision Oncology·2025
Data from A Phase II Trial of Naxitamab plus Stepped-up Dosing of GM-CSF for Patients with High-Risk Neuroblastoma in First Complete Remission
2025Open Access
Supplementary Table S1 from A Phase II Trial of Naxitamab plus Stepped-up Dosing of GM-CSF for Patients with High-Risk Neuroblastoma in First Complete Remission
2025Open Access
A Phase II Trial of Naxitamab plus Stepped-up Dosing of GM-CSF for Patients with High-Risk Neuroblastoma in First Complete Remission
Clinical Cancer Research·2025· 3 cited
Local control with radiotherapy to the primary site for high-risk neuroblastoma: A series of 126 patients in the proton era
International Journal of Particle Therapy·2025Open Access
The anti-GD2 monoclonal antibody naxitamab plus GM-CSF for relapsed or refractory high-risk neuroblastoma: a phase 2 clinical trial
Nature Communications·2025· 18 citedOpen Access
Reduced-Dose Radiation Therapy for High-Risk Neuroblastoma: Results from a Prospective Clinical Trial
International Journal of Radiation Oncology*Biology*Physics·2024· 1 cited
Abstract B055: Disease control in patients treated with naxitamab for refractory/relapsed high-risk neuroblastoma
Cancer Research·2024
Ovarian function in female survivors of high‐risk neuroblastoma
Pediatric Blood & Cancer·2024· 3 citedOpen Access
Evolutionary Strategies AI Addresses Multiple Technical Challenges in Deep Learning Deployment: Proof-of-Principle Demonstration for Neuroblastoma Brain Metastasis Detection
Journal of Imaging Informatics in Medicine·2024· 3 citedOpen Access
Patterns of improvement following initial response in patients treated with naxitamab for relapsed/refractory high-risk neuroblastoma.
Journal of Clinical Oncology·2024
Naxitamab-related adverse events within and across treatment cycles in patients with relapsed/refractory (R/R) high-risk neuroblastoma.
Journal of Clinical Oncology·2024· 3 cited
N9: Pilot study of novel shortened induction for high-risk neuroblastoma.
Journal of Clinical Oncology·2024· 1 cited
MRI compared to <sup>123</sup>I-MIBG scan for detection of central nervous system relapse in neuroblastoma.
Journal of Clinical Oncology·2024
Long Prime–Boost Interval and Heightened Anti-GD2 Antibody Response to Carbohydrate Cancer Vaccine
Vaccines·2024Open Access
Intraoperative Radiation Therapy for Relapsed or Refractory High-Risk Neuroblastoma: A 27-Year Experience
Practical Radiation Oncology·2024· 1 citedOpen Access
129P Naxitamab efficacy in patients with refractory/relapsed high-risk neuroblastoma and bone metastases as assessed by Curie score
Immuno-Oncology Technology·2023· 1 citedOpen Access
page 1 of 14Next →

Frequent Co-authors

Nai‐Kong V. Cheung(30), Kim Kramer(25), Michael P. LaQuaglia(18), Shakeel Modak(17), Irene Y. Cheung(13), Steven M. Larson(10), William L. Gerald(9), Glenn Heller(9), Suzanne L. Wolden(8), Mary Ann Bonilla(6), Paul A. Meyers(5), Irina Ostrovnaya(5), Ellen M. Basu(4), Stephen S. Roberts(4), N K Cheung(4), Norma Wollner(3), Neeta Pandit‐Taskar(3), S J Yeh(3), Karima Yataghene(3), Samuel D. J. Yeh(3)